-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bristol-Myers Squibb (BMS) announced today that the U.
Lung cancer is the leading cause of cancer death worldwide
Opdivo is a PD-1 immune checkpoint inhibitor designed to help restore anti-tumor immune responses
The application is based on the results of the pivotal Phase 3 clinical trial CheckMate-816, in which Opdivo in combination with chemotherapy, when administered preoperatively, demonstrated a pathological complete response (meaning that in surgically resected tissue or There was a statistically significant and clinically meaningful improvement in tissue biopsy samples without any sign of cancer, pCR) and event-free survival (EFS)
References:
[1] US Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer.
(Original abridged)